Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
Somerville, Massachusetts-based Finch Therapeutics closed a $90 million Series D financing, with plans to use the funds to advance the company’s lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.
Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
Watertown, Massachusetts-based SQZ Biotechnologies closed on a $65 million Series D round, led by Temasek with participation from another new large, U.S.-based fund.
The COVID-19 global pandemic, overcrowding of hospitals, the highly contagious virus affecting healthcare professionals and unrelated illnesses has led to a more than 1,000 percent increase of telemed application downloads and memberships. Is this a paradigm shift?
Foster City, California-based SutroVax closed on a Series D preferred stock financing worth $110 million, which was co-led by new investors RA Capital Management and Janus Henderson Investors.
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Lisle, Ill.-based medtech company Endotronix Inc. secured $45 million in a Series D financing round.